Form 4: Prelude Therapeutics Director Victor Sandor Granted Stock Options

Prelude Therapeutics Inc. Director Victor Sandor was granted 38,000 stock options with an exercise price of $1.04, vesting upon the earlier of the next annual stockholder meeting or one year from the grant date.

Summary

• Victor Sandor, a Director of Prelude Therapeutics Inc. (PRLD), was granted 38,000 Director Stock Options.
• The options have an exercise price of $1.04 per share.
• The grant date for these options was June 12, 2025.
• The options will fully vest upon the earlier of the Issuer's next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), contingent on continued service.
• The options expire on June 11, 2035.
• Following this transaction, Victor Sandor beneficially owns 38,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it represents a standard compensation event that aligns the director's interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of stock options to Director Victor Sandor aligns his interests with those of shareholders, incentivizing long-term value creation.
• The options have a long expiration date of June 11, 2035, providing a significant window for potential value realization.

Negatives

• No direct negatives are apparent from this standard insider transaction filing.

Future Outlook

The stock options granted to Director Victor Sandor are set to fully vest upon the earlier of Prelude Therapeutics Inc.'s next annual stockholder meeting or the one-year anniversary of the grant date (June 12, 2026), contingent on his continued service to the Issuer.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to align leadership incentives with long-term shareholder value creation. This filing reflects a routine compensation event for a director.

Related Party Transactions

• Grant of 38,000 Director Stock Options to Victor Sandor, a Director of Prelude Therapeutics Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's long-term interests with those of the shareholders, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The options granted to Director Victor Sandor are scheduled to vest upon the earlier of the Issuer's next annual stockholder meeting or June 12, 2026, subject to his continued service.

Key Dates

Keywords

Prelude Therapeutics, PRLD, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant